Vyvanse added to the Essential Formulary with Prior Authorization and Step Therapy
Effective June 1, 2022, Vyvanse capsules and chewable tablets will be added to the Essential Formulary as tier 4 medications. Vyvanse will require prior authorization with step therapy before a member will receive approval for the drug. The existing quantity limit of 1 capsule/tablet per day will remain in place.
No additional authorization is needed if a prior authorization was approved for a member in 2022, while Vyvanse required a formulary exception.
View the new coverage policy (PDF).
Blue Cross and Blue Shield of North Carolina does not discriminate on the basis of race, color, national origin, sex, age or disability in its health programs and activities. Learn more about our non-discrimination policy and no-cost services available to you.
Information in other languages: Español 中文 Tiếng Việt 한국어 Français العَرَبِيَّة Hmoob ру́сский Tagalog ગુજરાતી ភាសាខ្មែរ Deutsch हिन्दी ລາວ 日本語
© 2024 Blue Cross and Blue Shield of North Carolina. ®, SM Marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.